Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes

Inclusion Criteria: * Type 2 diabetes as defined by the American Diabetes Association; * Non-smoker; * Body mass index between 25.0 and 40.0 kg/m2; * Baseline HbA1c between 6.5 and 8.5%; * Baseline fasting plasma glucose \< 15.0 mmol/L; * Plasma triglyceride levels between 1.5 and 8.0 mmol/L (135 and 710 mg/dl) at week and -4; * Patients having received stable doses of metformin for at least 3 months before randomization; * Subjects must be willing to give written informed consent and able to adhere to dosing schedule, visit schedule and phone follow-up assessment; * Patients should be otherwise generally healthy, without elevations in hepatic transaminases or abnormal renal function or coagulation; * Patients having normal TSH at screening. Exclusion Criteria: * Patients with extreme dyslipidemias, such as familial hypercholesterolemia will be excluded; * Patients with type 1 diabetes, secondary form of diabetes or acute metabolic diabetic complications will be excluded; * Patients having received or being treated with insulin or a thiazolidinedione within the past 6 months will be excluded; * Subjects will be excluded if they have cardiovascular disease (CVD) (coronary heart disease, cerebrovascular disease or peripheral arterial disease) or if they are taking other medications known to affect lipoprotein metabolism (e.g. steroids, beta blockers, thiazide diuretics, lipid lowering agents, significant alcohol intake etc.); * Subjects who are in a situation or have any con…